×
Climb Bio EBIT 2021-2024 | CLYM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Climb Bio ebit from 2021 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
Climb Bio EBIT 2021-2024 | CLYM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Climb Bio ebit from 2021 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$174.4B
Vertex Pharmaceuticals (VRTX)
$125.1B
Regeneron Pharmaceuticals (REGN)
$111.8B
Bristol Myers Squibb (BMY)
$106.8B
Gilead Sciences (GILD)
$105.9B
CSL (CSLLY)
$97.5B
GSK (GSK)
$81.1B
Alnylam Pharmaceuticals (ALNY)
$36.4B
Argenex SE (ARGX)
$32.5B
BioNTech SE (BNTX)
$28.6B
Biogen (BIIB)
$27.9B
Illumina (ILMN)
$23.7B
Moderna (MRNA)
$22.2B
BeiGene (BGNE)
$22.1B
Genmab (GMAB)
$15.7B
BioMarin Pharmaceutical (BMRN)
$13.3B
Exact Sciences (EXAS)
$13.1B
Insmed (INSM)
$12.9B
Vaxcyte (PCVX)
$12.6B
Incyte (INCY)
$12.6B
Sarepta Therapeutics (SRPT)
$11.9B
Bio-Techne Corp (TECH)
$11.7B
QIAGEN (QGEN)
$10.1B
Bio-Rad Laboratories (BIO.B)
$9.3B
Legend Biotech (LEGN)
$9.1B
Roivant Sciences (ROIV)
$8.8B
Revolution Medicines (RVMD)
$8.2B
Repligen (RGEN)
$8B
Intra-Cellular Therapies (ITCI)
$7.8B
Ascendis Pharma (ASND)
$7.8B